José María Alunda

Prof. Dr. José María Alunda

Department of Animal Health, Faculty of Veterinary Medicine, Universidad Complutense de Madrid, Spain
orcid

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2021 in Microorganisms
Verified
Journal Article
Open access
PDF file
AOAna Isabel Olías-Molero
Ana Isabel Olías-Molero
CFConcepción de la Fuente
Concepción de la Fuente
MCMontserrat Cuquerella
Montserrat Cuquerella
JTJuan J. Torrado
Juan J. Torrado
José María AlundaJosé María Alunda
José María Alunda
Leishmaniasis is a vector-borne parasitic disease caused by Leishmania species. The disease affects humans and animals, particularly dogs, provoking cutaneous, mucocutaneous, or visceral processes depending on the Leishmania sp. and the host immune response. No vaccine for humans is available, and the control relies mainly on chemotherapy. However, currently used drugs are old, some are toxic, and the safer presentations are largely unaffordable by the most severely affected human populations. Moreover, its efficacy has shortcomings, and it has been challenged by the growing reports of resistance and therapeutic failure. This manuscript presents an overview of the currently used drugs, the prevailing model to develop new antileishmanial drugs and its low efficiency, and the impact of deconstruction of the drug pipeline on the high failure rate of potential drugs. To improve the predictive value of preclinical research in the chemotherapy of leishmaniasis, several proposals are presented to circumvent critical hurdles—namely, lack of common goals of collaborative research, particularly in public–private partnership; fragmented efforts; use of inadequate surrogate models, especially for in vivo trials; shortcomings of target product profile (TPP) guides.

1 September 2002 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
BBBéaTrice Bulle
BéaTrice Bulle
LMLaurence Millon
Laurence Millon
Jean-Mathieu BartJean-Mathieu Bart
Jean-Mathieu Bart
MGMontserrat Gállego
Montserrat Gállego
FGFrançoIse Gambarelli
FrançoIse Gambarelli
RPRenaud Piarroux
Renaud Piarroux
Currently the universally accepted standard procedure for characterizing and identifying strains of Leishmania is isoenzyme analysis. However, in the Mediterranean area, despite their very wide geographical distribution, most Leishmania infantum strains belong to zymodeme MON-1. In order to increase our understanding of polymorphism in strains of L. infantum , we developed PCR assays amplifying 10 microsatellites and sequenced PCR products. The discriminative power of microsatellite analysis was tested by using a panel of 50 L. infantum strains collected from patients and dogs from Spain, France, and Israel, including 32 strains belonging to zymodeme MON-1, 8 strains belonging to zymodemes MON-24, MON-29, MON-33, MON-34, or MON-80, and 10 untyped strains. Five of the microsatellites were polymorphic, revealing 22 genotypes, whereas the five remaining microsatellites were not variable. In particular, MON-1 strains could be separated into 13 different closely related genotypes. MON-33 and MON-34 strains also gave two additional genotypes closely related to MON-1, while MON-29, MON-24, and MON 80 strains exhibited more divergent genotypes. Among the foci examined, the Catalonian focus displayed a high polymorphism, probably reflecting isoenzyme polymorphism, while the Israeli focus exhibited a low polymorphism that could be consistent with the recent reemergence and rapid spread of canine leishmaniasis in northern and central Israel. The strains originating from the south of France and the Madrid, Spain, area displayed significant microsatellite polymorphism even though they were monomorphic by isoenzyme analysis. In conclusion, microsatellite polymorphism exhibits a high discriminative power and appears to be suitable for characterization of closely related strains of L. infantum in epidemiological studies.

1 March 2014 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
MCM. J. Corral
M. J. Corral
EGE. González-Sánchez
E. González-Sánchez
MCM. Cuquerella
M. Cuquerella
José María AlundaJosé María Alunda
José María Alunda
Current monotherapy against visceral leishmaniasis has serious side effects, and resistant Leishmania strains have been identified. Amphotericin B (AmB) has shown an extraordinary antileishmanial efficacy without emergence of resistance; however, toxicity has limited its general use. Results obtained showed, using a fixed-ratio analysis, that the combination of diallyl thiosulfinate (allicin) and AmB ranged from moderately synergic to synergic at low concentrations (0.07 μM AmB plus 35.45 μM allicin induced 95% growth inhibition). None of the treatments, alone or in combination, had noticeable adverse effects on macrophages (Mϕ) in the concentration range examined (allicin, 0.5, 1, 5 and 10 μM; AmB, 0.05, 0.075, and 0.1 μM). Allicin, AmB, or the combination did not affect the infection rate (percentage of infected Mϕ) of Leishmania . Allicin enhanced the activity of AmB on intracellular amastigotes of Leishmania donovani and L. infantum (ca. 45% reduction of amastigote burden with 0.05 μM AmB plus 10 μM allicin); this represented nearly a 2-fold reduction in the 50% inhibitory concentration (IC 50 ) of the antibiotic added alone. Results point toward the possible utility of testing this combination in vivo to reduce the toxicity associated with monotherapy with AmB.

29 March 2016 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
MCMaría J Corral
María J Corral
Elena Benito PeñaElena Benito Peña
Elena Benito Peña
MJM Dolores Jiménez-Antón
M Dolores Jiménez-Antón
LCLaureano Cuevas
Laureano Cuevas
Maria C Moreno-BondiMaria C Moreno-Bondi
Maria C Moreno-Bondi
José María AlundaJosé María Alunda
José María Alunda
Allicin has shown antileishmanial activity in vitro and in vivo. However the mechanism of action underlying its antiproliferative effect against Leishmania has been virtually unexplored. In this paper, we present the results obtained in L.infantum and a mechanistic basis is proposed. Exposure of the parasites to allicin led to high Ca2+ levels and mitochondrial reactive oxygen species (ROS), collapse of the mitochondrial membrane potential, reduced production of ATP and elevation of cytosolic ROS. The incubation of the promastigotes with SYTOX Green revealed that decrease of ATP was not associated with plasma membrane permeabilization. Annexin V and propidium iodide (PI) staining indicated that allicin did not induce phospholipids exposure on the plasma membrane. Moreover, DNA agarose gel electrophoresis and TUNEL analysis demonstrated that allicin did not provoke DNA fragmentation. Analysis of the cell cycle with PI staining showed that allicin induced cell cycle arrest in the G2/M phase. We conclude that allicin induces dysregulation of calcium homeostasis and oxidative stress, uncontrolled by the antioxidant defense of the cell, which leads to mitochondrial dysfunction and a bioenergetic catastrophe leading to cell necrosis and cell cycle arrest in the premitotic phase. Leishmaniasis is a vectorial parasitic disease caused by flagellate organisms from the genus Leishmania. Infection is present in over 80 countries and visceral forms are the second most fatal human parasitic disease. Control relies on chemotherapy but available drugs have important shortcomings such as toxicity, side effects, unaffordable price of the safest presentations and increasing reports of parasite resistance and clinical failures. Thus, new drugs are needed. Allicin, a molecule obtained from garlic, has shown antiproliferative effect against different cancer cells, bacteria, fungi and Protista including Leishmania. Insofar its mechanism of action is poorly known. Our results with L.infantum point towards allicin inducing high levels of intracellular calcium, redox inbalance, and mitochondrial dysfunction with reduction of ATP. These events lead to cell necrosis without evidence of apoptotic-like markers. The proposed model suggests the potential use of allicin against leishmaniasis, alone or in combination with other drugs with different mechanisms of action.

1 September 2004 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
JSJ. A. SánChez-Brunete
J. A. SánChez-Brunete
MDMaria Auxiliadora Dea-Ayuela
Maria Auxiliadora Dea-Ayuela
SRS. Rama
S. Rama
FBF. Bolás
F. Bolás
José María AlundaJosé María Alunda
José María Alunda
JTJuan J. Torrado
Juan J. Torrado
Hydrophilic albumin microspheres are proposed as a new delivery system for amphotericin B (AMB; AMB microspheres). The acute toxicity of AMB microspheres was lower than that of the AMB-deoxycholate (AMB-Doc) reference formulation in hamsters. Lethal doses in healthy and infected animals were improved at least eight times. Intravenous bolus administration of doses of AMB microspheres up to 40 mg/kg of body weight did not produce acute symptoms of toxicity. The efficacy of this new formulation was tested against Leishmania infantum- infected hamsters at doses of 2, 10, 20, and 40 mg/kg. With the 2-mg/kg dose, the activity of AMB, as assessed through the parasite load reductions in the liver and spleen and the evolution of antibody levels, was also improved ( P < 0.05) by use of the AMB microsphere system. At the higher doses of 10, 20, and 40 mg/kg, reductions in parasite levels of more than 99% were achieved in the liver and spleen after the administration of AMB microspheres. A pharmacokinetic study was performed to study the serum, liver, and spleen AMB concentrations after administration of AMB microspheres and the reference formulation. Interestingly, a significant accumulation of AMB in the spleen and liver was observed after AMB microsphere administration. Our results suggest that this new formulation is a promising alternative to the conventional AMB-Doc formulation for the treatment of visceral leishmaniasis.

1 May 2007 in Veterinary Immunology and Immunopathology
Verified
Journal Article
Closed access
Luís CardosoLuís Cardoso
Luís Cardoso
HSH.D.F.H. Schallig
H.D.F.H. Schallig
A. Cordeiro-Da-SilvaA. Cordeiro-Da-Silva
A. Cordeiro-Da-Silva
MCM. Cabral
M. Cabral
José María AlundaJosé María Alunda
José María Alunda
MRM. Rodrigues
M. Rodrigues